Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer

Prostate

Volumn 35, Issue 3, 1998, Pages 165-177

  Wang, Y Z ^a   Wong, Y C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

IGF 1; Prostate carcinogenesis; Receptors; Sex hormones; VEGF

Indexed keywords

SOMATOMEDIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOMA IN SITU; ESTRADIOL BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TESTOSTERONE BLOOD LEVEL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; EPITHELIAL CELLS; ESTRADIOL; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR I; LYMPHOKINES; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RATS; RECEPTOR, IGF TYPE 1; STROMAL CELLS; TESTOSTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032525021     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980515)35:3<165::AID-PROS2>3.0.CO;2-G     Document Type: Article

References (36)

1. McNeal JE: Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340-345.
2. McNeal JE: The prostate gland: Morphology and pathobiology. Monogr Urol 1983;4:1-33.
3. Geller AU: Overview of benign prostatic hypertrophy. Urology [Suppl] 1989;34:57-63.
4. Carter BS, Carter HB, Isaacs JT: Epidimiological evidence regarding predisposing factors to prostate cancer. Prostate 1990; 16:187-197.
5. Meikle AW, Smith JA, West DW: Familial factors affecting prostatic cancer risk and plasma sex steroid levels. Prostate 1985;6: 121-128.
6. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;75:45-48.
7. Zumoff B, Strain GW, Kream J, O'Connor J, Rosenfeld RS, Levin J, Fukushima DK: Age variation of the 24-hour mean plasma concentrations of androgens, estrogens and gonadotropins in normal adult men. J Clin Endocrinol Metab 1982;54:534-538.
8. Noble RL: Development of androgen-stimulated transplants of Noble rat carcinoma of the dorsal prostate and their response to sex hormones and tamoxifen. Cancer Res 1980;40:3551-3554.
9. Pollard M, Synder DL, Luckert PH: Dihydrotestosterone does not induce prostate adenocarcinoma in L-W rats. Prostate 1987; 10:325-331.
10. Drago JR: The induction of Noble rat prostatic carcinomas. Anticancer Res 1984;4:255-256.
11. Noble RL: Prostate carcinoma of the Noble rat in relation to hormones. Int Rev Exp Pathol 1982;23:113-159.
12. Leav I, Ho SM, Ofner P, Merk FB, Kwan PWL, Damassa D: Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 1988;80:1045-1053.
13. Leav I, Merk FB, Kwan PWL, Ho SM: Androgen-supported estrogen-enhanced epithelial proliferation in the prostate of intact Noble rats. Prostate 1989;15:23-40.
14. Ho SM, Roy D: Sex hormone induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett 1994;84:155-162.
15. Ho SM, Yu M: Selective increase in type II estrogen-binding sites in the dysplastic dorsolateral prostates of Noble rats. Cancer Res 1993;53:528-532.
16. Hayward SW, Bosen MA, Cunha GR: Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol [Suppl] 1997;79:18-26.
17. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA: Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 1992;13:465-475.
18. Chung LW: The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 1995;23:33-42.
19. Leav I, Kwan PW, Merk FB, Chang C, Ho SM: Immunohistochemical and in situ hybridization studies of androgen receptor expression in a transplantable androgen-independent prostatic carcinoma line (AIT) of Noble rats. Lab Invest 1992;67:788-795.
20. Bosland MC: Animal models for the study of prostate carcinogenesis. J Cell Biochem [Suppl] 1992;16:89-98.
21. He B, Wang YZ, Wong YC: Differential expression of transforming growth factor-α (TGF-α) in dorsolateral (DLP) and ventral prostate (VP) during prostate carcinogenesis. AACR Proc 1996; 37:148.
22. Jager GJ, Barentz JO, Ruijter ET, de-la-Rosette JJ, Oosterhof GO: Primary staging of prostate cancer. Eur Radiol 1996;6:134-139.
23. Ware JL: Prostate cancer progression. Implications of histopathology. Am J Pathol 1994;145:983-993.
24. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ: Ki67 labeling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-441.
25. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van-de-Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 1991; 174:1275-1278.
26. Thrasher JB, Tennant MK, Twomey PA, Hansberry KL, Wettlaufer JN, Plymate SR: Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: Clinical correlations. J Urol 1996;155:999-1003.
27. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H: Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-105.
28. Cohen P, Peehl DM, Lamson G, Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-407.
29. Barni T, Vannelli BG, Sadri R, Pupilli C, Ghiandi P, Rizzo M, Selli C, Serio M, Fiorelli G: Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization. J Clin Endocrinol Metab 1994;78:778-783.
30. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG: Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410-1415.
31. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-517.
32. Iwamura M, Sluss PM, Casamento JB, Cockett AT: Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
33. Kaicer EK, Blat C, Harel L: IGF-I and IGF-binding proteins: Stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 1991;4:231-237.
34. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102-1106.
35. Tennant M, Thrasher J, Twomey P, Drivdahl R, Birnbaum R, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-3782.
36. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL: Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997;138:1728-1735.